DGAP-News: MagForce AG / Key word(s): Miscellaneous/Miscellaneous
MagForce AG Announces that Cologne University Hospital has Initiated
Commercial NanoTherm(TM) Treatments for Brain Cancer
07.05.2015 / 08:30
---------------------------------------------------------------------
MagForce AG Announces that Cologne University Hospital has Initiated
Commercial NanoTherm(TM) Treatments for Brain Cancer
Berlin, Germany and Nevada, USA, May 7, 2015 - MagForce AG (Frankfurt,
Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device
company in the field of nanomedicine focused on oncology, today announced
that the Center for Integrated Oncology at Cologne University Hospital,
headed by Prof. Dr. med. Roland Goldbrunner, has initiated NanoTherm(TM)
therapy in the commercial setting for the treatment of brain cancers in
addition to the ongoing post-marketing study.
This represents the inauguration of the third clinic in Germany that offers
the benefit of MagForce's NanoTherm(TM) therapy for brain cancer patients
in addition to the University Hospitals in Münster and Kiel.
"With Cologne we have established another renowned medical center for
treating brain cancer patients with our proprietary NanoTherm(TM) therapy
also in the commercial setting. This expansion provides more geographic
opportunites for treatment within Germany. We are very happy to see
increasing interest by private pay patients and also with the successful
interaction with the key opinion leaders in the medical community,"
commented Dr. Ben J. Lipps, CEO of MagForce AG and MagForce USA, Inc.
Additional to the increasing commercial business in Europe, the key focus
of MagForce is on the US market.
"We continue to be on track with our preparations for the approval process
in the U.S. for both brain and prostate cancer," Dr. Ben J. Lipps added.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange
(MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc.
is a leading medical device company in the field of nanomedicine focused on
oncology. The Group's proprietary NanoTherm(TM) therapy enables the
targeted treatment of solid tumors through the intratumoral generation of
heat via activation of superparamagnetic nanoparticles. Mithril Capital
Management, a growth-stage technology fund founded by Ajay Royan and Peter
Thiel, along with MagForce AG, are investors and strategic partners in
MagForce USA, Inc.
NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the
therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R),
and NanoActivator(R) are trademarks of MagForce AG in selected countries.
For more information, please visit: www.magforce.com
Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list.
Disclaimer
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as "expects", "aims",
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or
"will". Such forward-looking statements are based on our current
expectations and certain assumptions, which may be subject to a variety of
risks and uncertainties. The results actually achieved by MagForce AG may
substantially differ from these forward-looking statements. MagForce AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments, which differ from those, anticipated.
Contact:
MC Services AG
Anne Hennecke
P +49 211 529252-22
F +49 211 529252-29
E-mail: anne.hennecke@mc-services.eu
---------------------------------------------------------------------
07.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: MagForce AG
Max-Planck-StraÃe 3
12489 Berlin
Germany
Phone: +49 (0)30 308 380 0
Fax: +49 (0)30 308 380 99
E-mail: info@magforce.com
Internet: www.magforce.com
ISIN: DE000A0HGQF5
WKN: A0HGQF
Listed: Regulated Unofficial Market in Berlin, Dusseldorf,
Stuttgart; Open Market (Entry Standard) in Frankfurt
End of News DGAP News-Service
---------------------------------------------------------------------
354083 07.05.2015
DGAP-News: MagForce AG Announces that Cologne University Hospital has Initiated Commercial NanoTherm(TM) Treatments for Brain Cancer
| Source: EQS Group AG